NEW YORK, Aug. 12, 2016 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”)
and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-06106, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Tokai securities between June 24, 2015 and July 25, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
If you are a shareholder who purchased Tokai securities during the Class Period, you have until September 30, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at email@example.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
Tokai is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate is galeterone, an oral small molecule that was, at all relevant times, in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) there were significant structural problems with the trial design for Tokai’s pivotal Phase 3 galeterone study, ARMOR3-SV; (ii) consequently, ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; (iii) as a result, commercialization of galeterone was less likely and/or imminent than Tokai had led investors to believe; and (iv) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Tokai’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On November 2, 2015, Richard Pearson published an article on the investment website Seeking Alpha, entitled “What’s Wrong With Tokai Pharmaceuticals?” (the “Pearson Report”). The Pearson Report described structural problems with the design of the Company’s ARMOR3-SV trial.
On this news, Tokai’s share price fell $0.07, or 0.63%, to close at $10.98 on November 2, 2015.
On July 26, 2016, Tokai announced plans “to discontinue the ARMOR3-SV clinical trial, our pivotal Phase 3 study” of galeterone.
On this news, Tokai’s share price plummeted by $4.10, or nearly 79%, to close at $1.10 on July 26, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-tokai-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadline–tkai-300313061.html
SOURCE Pomerantz LLP
Copyright (C) 2016 PR Newswire. All rights reserved